linjc16/ctgov huggingface dataset:
The Feasibility and Application of Intraoperative Ultrasound to Evaluate Femoral Head Shaping

Study Overview
=================
Brief Summary
-----------------
To assess the feasibility of using intraoperative ultrasound to evaluate the femoral head formation; to evaluate the improvement of the forming effect using the intraoperative ultrasound combined with c-arm.

Detailed Description
-----------------
Ultrasound can provide a multi-directional scan of the femoral head and neck junction, and the range of evaluation is larger than that of the intraoperative c-arm. The study was to assess the feasibility of using intraoperative ultrasound to evaluate the femoral head formation; to evaluate the forming of the femoral head and the improvement of the forming effect using the intraoperative ultrasound combined with c-arm.

Official Title
-----------------
The Feasibility and Application of Intraoperative Ultrasound to Evaluate Femoral Head Shaping

Conditions
-----------------
Femoroacetabular Impingement

Intervention / Treatment
-----------------
* Device: ultrasound evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with hip pain; Cam type (alpha Angle > 50°) impingement and glenoid labrum laceration Exclusion Criteria: Previous hip surgery; Patients with subosseous cystic degeneration of synovitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ultrasonic and c-arm combination group<br>Ultrasound and c-arm were combined to evaluate intraoperatively conditions | Device: ultrasound evaluation<br>* According to the sequential test, the enrolled patients were divided into ultrasound evaluation group and no ultrasound evaluation group.<br>|
| c-arm group<br>c-arm group was used to evaluate intraoperatively conditions | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS scale | Visual analogue scale（VAS）was used to measure the pain score. The minimum and maximum values were 0 and 10. The higher score, the worse pain. | 1 year after operation | 
| MHHS scale | Modified Harris Hip Score (MHHS) scale was used to measure the symptoms of joint. The minimum and maximum values were 0 and 91. The higher score, the better. | 1 year after operation | 
| Hip CT | Routine postoperative hip CT was used to understand the joint morphology. | 1 day after operation | 
| Hip X-ray | Routine hip X-ray at the Dunn position was conducted. | 1 day after operation |
Cochlear Implants in Post-lingually Children: Results After 10 Years

Study Overview
=================
Brief Summary
-----------------
Objectives: To assess a group of post-lingually children after 10 years of implantation with regard to speech perception, speech intelligibility, and academic/occupational status. Study Design: A prospective transversal study. Setting: Pediatric referral center for cochlear implantation. Patients: Ten post-lingually deafened children with Nucleus and Med-El cochlear implants. Interventions: Speech perception and speech intelligibility tests and interview. Main Outcome Measures: The main outcome measures were score of Hint sentences recognition (silence and noise), speech intelligibility scores(write-down intelligibility and rating scale scores) and academic/ occupational status.

Official Title
-----------------
Cochlear Implants in Post-lingually Children: Results After 10 Years

Conditions
-----------------
Deafness, Hearing Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: postlingually deaf age at cochlear implant: < 18 years more than 10 years of cochlear implant use Exclusion Criteria: other disabilities
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
results, cochlear implant, children, follow up
PCOS (Polycystic Ovarian Syndrome) Patients

Study Overview
=================
Brief Summary
-----------------
The Prospective Cohort Study for PCOS Patients was set up to investigate the short- and long-term health consequences in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, China.

Detailed Description
-----------------
Polycystic ovary syndrome (PCOS) affects 8-13% of women. It is a multifaceted condition characterized by chronic anovulation and excess ovarian activity. Since last decade, Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD) has been used in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, and Henan Province Key Laboratory for Reproduction and Genetics. Information of patients (POI, PCOS, Endometriosis, azoospermia, ect) were recorded comprehensively. The current project plans to recruit PCOS participants in our center. Biological samples, questionnaires and short/long term health data will be collected. The study is aimed to provide evidence for PCOS prognosis.

Official Title
-----------------
Prospective Cohort Study for PCOS Patients in Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD)

Conditions
-----------------
Health Related

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PCOS patients diagnosed with The Rotterdam diagnostic criteria. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of serum FSH (Follicle stimulating hormone) | mIU/mL | From date of inclusion, assessed by each 12 month, up to 40 years | 
| Level of serum LH (Luteinizing hormone) | mIU/mL | From date of inclusion, assessed by each 12 month, up to 40 years | 
| Level of T (Testosterone) | ng/ml | From date of inclusion, assessed by each 12 month, up to 40 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight | Recorded in Kilograms | From date of inclusion, assessed by each 12 month, up to 40 years | 
| Height | Recorded in centimeters | From date of inclusion, assessed by each 12 month, up to 40 years |
Detection of Pathological Lymphocytes in Patients With Autoimmune Disease

Study Overview
=================
Brief Summary
-----------------
This study will help the investigators design a method to detect the disease-causing immune cells in patients with rheumatoid arthritis (RA). Such methods are not currently available, but if successful, would help scientists to better understand the causes of RA.

Detailed Description
-----------------
The investigators are interested in learning about the immune cells in the blood that contribute to disease in patients with rheumatoid arthritis (RA). They have developed a method for identifying a specific type of immune cells that can react against normal tissues in the body. In this study, the investigators will enroll RA patients from the University of Minnesota clinics, collect blood samples from enrolled patients, and process the blood samples to isolate DNA, RNA, serum, and blood cells. They will use the serum to detect whether specific autoantibodies (Anti-cyclic Citrullinated Peptide, or anti-CCP) are present. In cases where anti-CCP antibodies are detected, the investigators may quantify the numbers of immune cells present that contain receptors with the same anti-CCP specificity. They may also test whether the numbers of immune cells with these receptors correlate with measures of disease activity in RA patients.

Official Title
-----------------
Detection of Pathological Lymphocytes in Patients With Autoimmune Disease

Conditions
-----------------
Arthritis, Rheumatoid

Intervention / Treatment
-----------------
* Other: No intervention (observational)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of rheumatoid arthritis Exclusion Criteria: Use of rituximab immediately prior to visit Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rheumatoid Arthritis<br>Rheumatoid arthritis patients | Other: No intervention (observational)<br>* No intervention (observational)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DAS28-ESR |  | 6 months |
Contrast Echocardiography in Patients With Pulmonary Arteriovenous Malformations (PAVMs)

Study Overview
=================
Brief Summary
-----------------
Pulmonary arteriovenous malformations (PAVMs) are thin-walled abnormal vessels which provide direct capillary-free communications between the pulmonary and systemic circulations. Patients with PAVMs have usually have low blood oxygen levels and are at risk of other complications including strokes, brain abscesses, pregnancy-related complications and haemorrhage. We hypothesise that the complications of PAVM patients arise from their PAVMs and not the more recognised intracardiac forms of shunting. We propose to perform echocardiograms to enable assessment of the presence of other causes of capillary-free communications between the pulmonary and systemic circulations.

Official Title
-----------------
The Evaluation of Intra-cardiac Shunts in Patients With Pulmonary Arteriovenous Malformations

Conditions
-----------------
Pulmonary Arteriovenous Malformations

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with pulmonary arteriovenous malformations (PAVMs) Exclusion Criteria: unable to provide informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

Study Overview
=================
Brief Summary
-----------------
Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy. The prognosis is good, but some patients will have recurrent or persistent disease after concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop distant metastases that can be treated with good results. The aim of this study is to identify and describe functional outcome in patients diagnosed with anal cancer. We will study patients from diagnosis, try to identify early toxicity to treatment and then identify long-term morbidity.

Official Title
-----------------
ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

Conditions
-----------------
Anal Cancer

Intervention / Treatment
-----------------
* Other: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Anal squamous carcinoma diagnosed within the last 2 months Exclusion Criteria: -No informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with a new diagnosis of anal cancer<br>All patients identified at our national tumour board will be offered to participate | Other: Questionnaires<br>* Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoL | Health related QoL at | 3 months after diagnosis | 
| Urinary function | Evaluate urinary dysfunction | 3 months after diagnosis | 
| Bowel function | Evaluate bowelfunction | 3 months after diagnosis | 
| Sexual function | Evaluate sexual function | 3 months after diagnosis | 
| Toxicity related to treatment | Number of patients with severe toxicity from the chemoradiotherapy | 3 months after diagnosis | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoL | QoL measured on a 7 point likert scale at 12 months | 12 months after diagnosis | 
| Urinary function | Urinary dysfuntion measured as incontinence at 12 months | 12 months after diagnosis | 
| Bowel function | Bowel dysfunction measured at 12 months | 12 months after diagnosis | 
| Sexual function | Sexual dysfunction measured at 12 months | 12 months after diagnosis | 
| QoL | QoL measured on a 7 point likert scale at 3 years | 3 years after diagnosis | 
| Urinary function | Urinary function at 3 years | 3 years after diagnosis | 
| Bowel funcction | Bowel dysfunction at 3 years | 3 years after diagnosis | 
| Sexual function | Sexual dysfunction at 3 years | 3 years after diagnosis |
Patient Journey in Hospital With Heart Failure in Turkish Population

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests, precipitating and risk factors, management of from intensive care unit or coronary care unit to hospital discharge, length of stay in the intensive care unit and hospital, in-hospital mortality and discharge medications of hospitalized acute heart failure patients in Turkish population.

Detailed Description
-----------------
The etiologies, precipitating factors, demographics, clinical characteristics, management and outcome of patients admitted in hospital with acute heart failure in Turkish population will be recorded.

Official Title
-----------------
A Multicentre, Prospective, Observational, Hospital-based Registry of Patients With Acute Heart Failure Those Whose Care Was Guided by a Cardiologist in Turkey

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients >18 years olds Clinical diagnosis of acute heart failure Admitted to the participating hospitals Exclusion Criteria: Patients <18 years old Patients with acute heart failure who are discharged from the emergency room without admission. Failure to obtain informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to European Heart Failure Guideline | To assess number of patients managed and treated following the last European Heart Failure Guidelines | Admission to Hospital (Enrollment) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of Hospitalisation | Length of stay in hospital in Turkish population admitted to study | In-Hospital | 
| Mortality | All cause death | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Failure, Diagnosis, Management
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.

Study Overview
=================
Brief Summary
-----------------
Computed tomographic pulmonary angiography (CTPA) is considered the gold standard for the diagnosis of pulmonary embolism (PE). PE is a potentially fatal disease in which a thrombus is lodged into a pulmonary artery blocking blood flow and potentially leading to respiratory distress, acute right cardiac failure or death. Therefore early and correct diagnosis is crucial. The diagnostic and clinical value of CTPA has already been firmly substantiated. Unfortunately up to 7.3% of PE scans are still deemed to be non-diagnostic, for example due to insufficient contrast enhancement in the target arteries. Therefore future research should focus on two important aspects of CT imaging. On the one hand optimal enhancement for the individual patient, on the other hand preventing additional risk of CT imaging - namely contrast induced nephropathy (CIN) and radiation risk. Thus the purpose of our study will be to optimize radiation dose settings (e.g. tube voltage, tube current) and CM application for the individual patient in CTPA.

Official Title
-----------------
Optimizing Tube Voltage Settings and Injection Parameters for the Individual Patient in CT Pulmonary Angiography.

Conditions
-----------------
Pulmonary Embolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Suspicion of pulmonary embolism Exclusion Criteria: Severe allergy against Iopromide or any of the ingredients, previous severe CM reaction (according to current ESUR guidelines), renal insufficiency, pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Image quality | Evaluation of subjective and objective image quality based on individualized CTPA protocols | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of radiation dose | Effect of individualized tube voltage settings on radiation | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Embolism, Multidetector Computed Tomography, Radiation Dosage, Contrast Media, Individualized Medicine
Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers

Study Overview
=================
Brief Summary
-----------------
This research project addresses the hypothesis that a neurocognitive profile characterized by impairment of response inhibition and sustained attention may be a risk factor for smoking initiation and nicotine dependence among young women. Nicotine has short- term, facilitating effects on attention and response inhibition. Therefore, individuals who are impaired on cognitive functions such as these and initiate cigarette smoking may be more likely to maintain the habit and develop nicotine dependence. The research protocol specifically tests whether administration of nicotine to non-abstinent, regular cigarette smokers improves cognitive function in those domains where the participants had previously been shown to manifest performance deficits

Official Title
-----------------
Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers: A Double-Blind, Within-Subjects, Placebo-Controlled Study

Conditions
-----------------
Smoking, Nicotine Dependence, Tobacco Use Disorder, Nicotine Use Disorder

Intervention / Treatment
-----------------
* Drug: Nicotine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Reported smoking cigarettes on a daily basis at the time of the original study and continue to smoke currently Manifested poor performance on the MFFT (The neurocognitive test that yielded differences between smokers and non-smokers) Competent and willing to give written informed consent Exclusion Criteria: Pregnancy, breast-feeding, non-use of contraception such that the possibility of pregnancy cannot be excluded Intake of any medication that may potentially interact with nicotine. Any current or past medical condition that represents a contra-indication to nicotine administration.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Nicotine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neurocognitive functions |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nicotine Dependence, Smoking, Tobacco Use Disorder, Nicotine Use Disorder